Assessment of the economic efficiency of the anesthetic nefopam in therapy postoperative pain

2018

Качественная клиническая практика, Vol 0, Iss 2, Pp 27-34 (2018)

The purpose of this pharmacoeconomic analysis was to determine the drug Nefopam economic feasibility of its use for postoperative pain relief in terms of the health system of the Russian Federation. Target population are Russian patients older than 18 years with moderate to severe pain after surgery, which requires the use of postoperative analgesia. In the context of this pharmacoeconomic analysis of patients treated with the assessment of the physiological status of not higher than class I or II on the scale of the American Association of Anesthesiologists. Clinical utility criterion: change numeric scale pain score (NPS — Numeric Pain Scale). In calculating the cost-utility ratio (CUR) following data were obtained: the cost of therapy at least a separate application ketoprofen — 19.80 rubles; CUR minimum figure in the application of multimodal anesthesia — 13.78 rubles. Budget impact analysis showed that the cost savings when using multimodal analgesia will be 574,662 rubles 1000 patients compared with nefopam; and in a separate application of ketoprofen — 21 538 rubles.

article

Russian

Izdatelstvo OKI, 2018.

нефопам, морфин, кетопрофен, опиоидсберегающая терапия, послеоперационная анестезия, послеоперационная боль, анальгезия, мультимодальная анальгезия, неопиоидные анальгетики, контролируемая пациентом анальгезия, фармакоэкономика, анализ полезности затрат, анализ влияния на бюджет, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441